Anzeige
Mehr »
Dienstag, 23.12.2025 - Börsentäglich über 12.000 News
Breaking News: "Königs-Exosomen" senken Entzündungslevel um 90%…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0Q8LD | ISIN: BMG210A71016 | Ticker-Symbol: MX6A
Frankfurt
22.12.25 | 08:59
0,835 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
GRAND PHARMACEUTICAL GROUP LTD Chart 1 Jahr
5-Tage-Chart
GRAND PHARMACEUTICAL GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8350,95508:18
0,8700,93008:14

Aktuelle News zur GRAND PHARMACEUTICAL GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiGRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S INDEPENDENTLY DEVELOPED, BLOCKBUSTER, GLOBALLY INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE, GPN01530, ...-
08.12.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S CLASS 1 INNOVATIVE TRADITIONAL CHINESE MEDICINE GPN01360 ...1
04.12.GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2021 AND 2022 ANNUAL REPORTS1
10.11.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: GLOBAL INNOVATIVE COMBINATION PRODUCT RYALTRIS NASAL SPRAY IS APPROVED TO BE COMMERCIALIZED IN CHINA1
09.10.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE REGISTRATION CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE TEMPERATURE-SENSITIVE EMBOLIC ...-
24.09.GRAND PHARMA (00512): INTERIM REPORT 2025-
24.09.GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
GRAND PHARMACEUTICAL GROUP Aktie jetzt für 0€ handeln
24.09.GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
23.09.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: TREPROSTINIL INJECTION (20ML: 50MG) IS GRANTED A DRUG REGISTRATION CERTIFICATE3
08.09.Sirtex Medical Inc.: Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres324Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading...
► Artikel lesen
08.09.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ...2
27.08.GRAND PHARMA (00512): CONTINUING CONNECTED TRANSACTION-
19.08.GRAND PHARMA (00512): 2025 INTERIM RESULTS ANNOUNCEMENT1
05.08.GRAND PHARMA (00512): DATE OF BOARD MEETING1
28.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: RESTRUCTURING OF THE SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER GROUP2
22.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN AN INTERNATIONAL MULTICENTER PHASE ...1
17.07.GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT TO CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT1
17.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST NASAL SPRAY PRODUCT OF THE GROUP FOR THE TREATMENT OF DRY EYE DISEASE, OC-01, ACHIEVES ...2
07.07.SIR-Spheres Y-90 Harz-Mikrosphären von Sirtex Medical erhalten FDA-Zulassung für die Behandlung des inoperablen Leberzellkarzinoms450Woburn, Massachusetts (ots/PRNewswire) - Erweiterte Indikation macht SIR-Spheres® zur ersten und einzigen Radioembolisationstherapie in den USA, die sowohl zur Behandlung des inoperablen Leberzellkarzinoms...
► Artikel lesen
07.07.Sirtex Medical Inc.: Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma297Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1